Details for New Drug Application (NDA): 209986
✉ Email this page to a colleague
NDA 209986 describes COBICISTAT, which is a drug marketed by Mylan Labs Ltd and is included in one NDA. Additional details are available on the COBICISTAT profile page.
The generic ingredient in COBICISTAT is cobicistat. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cobicistat profile page.
The generic ingredient in COBICISTAT is cobicistat. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cobicistat profile page.
Summary for 209986
| Tradename: | COBICISTAT |
| Applicant: | Mylan Labs Ltd |
| Ingredient: | cobicistat |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 209986
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
| Approval Date: | Feb 7, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
